
# Fig. 1.




3283, cyclo $VEGF_{189}$ (152-163) mutant: CVQDPQT*O*K*O*SC
3284, cyclo $VEGF_{189}$ (154-161) mutant: CDPQTOKC
3285, cyclo $VEGF_{189}$ (152-163) mutant: YCVQDPQT*O*K*O*SCY
3286, dicyclo $VEGF_{165}$ (111-138): ARQENPCGPC'SERRKHLFVQDPQTCKC'S
3287/F9, dicyclo $VEGF_{165}$ (138-165): SC'KNTDSRCKARQLELNERTC'RCDKPRR
3287/F10, dicyclo $VEGF_{165}$ (138-165): SC'KNTDSRCKARQLELNERTC'RCDKPRR

O = Aminobutyric acid

Fig. 2.



Specific 125I-VEGF binding, % of control
PAE/NP1
PAE/Flt1
PAE/KDR
○ HUVEC, IC50 = 26 μM
● PAE/NP1,IC50 = 3 μM
log [EG3287] (M)
150
100
50
0
-7
-6
-5
-4
-3

Fig. 3.




EG3287, μM
0 10 30 100
VEGF-A + EG3287
0 10 30 100
pY1054/1059-KDR
Total KDR

Fig. 4.


● VEGF165, IC50 = 1 nM
○ EG3287, IC50 = 3 μM
Specific 125I-VEGF binding, % of control
150
100
50
0
-50
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2
Concentration, log M